Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Catalin Toma Added: 1 week ago
Dr Catalin Toma joins us to share practical guidance on catheter-based intervention for pulmonary embolism, offering clinical insights for interventionalists navigating this increasingly active space.As catheter-directed therapies for PE continue to evolve and expand into more centres, questions around patient selection, technique, and post-procedural management remain front of mind for the… View more
Author(s): Karim Al-Azizi , Devi Nair , Added: 1 month ago
In this expert discussion, DrKarim Al-Azizi(Baylor Scott & White The Heart Hospital, US), Editor-in-Chief of the Transcatheter Academy, is joined by steering committee members DrDevi Nair(Chief VP of Research, Arkansas Heart Hospital, US) and DrMegan Coylewright(Essentia Health, US) to unpack the landmark CHAMPION-AF trial (NCT05964200) and its implications for stroke prevention in atrial… View more
Author(s): Tiziana Claudia Aranzulla Added: 9 months ago
ESC Congress 2025 - Evolocumab on top of lipid lowering therapy(LLT) reduced adverse vascular events at 12 months.Dr Tiziana Claudia Aranzulla (Mauriziano Umberto Hospital, Turin, IT) joins us to discuss findings from CARUSO (NCT04730973). The trial aimed to assess the efficacy of evolocumab with traditional LLT compared to traditional LTT alone in the stabilisation and regression of carotid… View more
Added: 4 months ago Source:  Radcliffe Vascular
The optimal management for asymptomatic carotid stenosis has been a subject of debate, particularly with advancements in medical therapy. New findings from the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) provide clarity, suggesting a benefit for carotid-artery stenting when added to intensive medical management.¹MethodologyCREST-2 involved… View more
Added: 4 months ago Source:  Radcliffe Vascular
The optimal management for patients with high-grade asymptomatic carotid stenosis remains a key clinical question, particularly with advancements in medical therapy and revascularisation techniques. The CREST-2 trials were designed to assess whether adding revascularisation to intensive medical management provides a greater benefit than intensive medical management alone in this patient… View more
Author(s): Victoria Delgado Added: 5 months ago
ESC Guideline Updates in Transcatheter Valve Interventions with Dr Victoria DelgadoThis presentation examines critical updates across the spectrum of valvular heart disease, from expanded TAVR indications to novel approaches for tricuspid regurgitation. Dr Delgado addresses the evolution of treatment algorithms, emphasizing the central role of multimodality imaging in accurate diagnosis and… View more
Author(s): Nadira Hamid , Rahul P Sharma Added: 7 months ago
TCT 2025 — Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr Rahul P Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease.The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and… View more